PT  - JOURNAL ARTICLE
AU  - DIETMAR W. SIEMANN
AU  - WENYIN SHI
TI  - Dual Targeting of Tumor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or OXi4503)
DP  - 2008 Jul 01
TA  - Anticancer Research
PG  - 2027--2031
VI  - 28
IP  - 4B
4099  - http://ar.iiarjournals.org/content/28/4B/2027.short
4100  - http://ar.iiarjournals.org/content/28/4B/2027.full
SO  - Anticancer Res2008 Jul 01; 28
AB  - Background: This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents. Materials and Methods: Human clear cell renal carcinoma (Caki-1) tumors were established in nude mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay. Results: The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503. Conclusion: Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved